Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Katherine Liao¹, Chandrasekar Gopalakrishnan², Jinoos Yazdany³, Griffith Bell⁴, Suraj Mothi⁵, Genevieve Gauthier⁶, Arne Yndestad⁷ and Milena Gianfrancesco⁸, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ²OM¹ Inc, Boston, MA, USA, Boston, ³UCSF, San Francisco, CA, ⁴Pfizer Inc, New York, NY, USA, Boston, MA, ⁵OM¹ Inc, Boston, MA, USA, Boston, MA, ⁶Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ⁷Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁸Pfizer Inc, New York, NY, USA, New York, NY
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
Abstract Number: 1088 • ACR Convergence 2025
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: The broad use of immune checkpoint inhibitors (ICIs) in oncology has led to the emergence of ICI-induced inflammatory arthritis (ICI-IA). The aim of this…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Ernest Choy¹, Marco Gattorno², Kamila Klama³, Andras Illes⁴, Peter Baker⁵, Maria Romanova Michailidi⁶ and Anna Zubrzycka-Sienkiewicz⁷, ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ²IRCCS G. Gaslini, Genova, Genoa, Italy, ³Solumed Clinical Research Center, Poznan, Poland, ⁴Fresenius Kabi SwissBioSim, Eysin, Switzerland, ⁵Fresenius Kabi Biopharma, Eysins, Switzerland, ⁶University of Geneva, Eysins, Switzerland, ⁷Reumatika - Centrum Reumatologii, Warszawa, Poland
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 1586 • ACR Convergence 2025
Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Stefano Di Donato¹, Marie-Elise Truchetet², Marco Minerba³, Oliver Distler⁴, JUAN JOSE ALEGRE SANCHO⁵, Yolanda Braun Moscovici⁶, Christina Bergmann⁷, Petros Sfikakis⁸, Jeska de Vries-Bouwstra⁹, Murray Baron¹⁰, Silvia Bellando-Randone¹¹, Lorenzo Dagna¹², Christopher Denton¹³, Madelon Vonk¹⁴, Vanessa Smith¹⁵, Ivan Castellvi¹⁶, Gabriela Riemekasten¹⁷, Andra Balanescu¹⁸, Masataka Kuwana¹⁹, Maria De Santis²⁰, Kamal Solanki²¹, Anastas Batalov²², Vahan Mukuchyan²³, Marco Matucci-Cerinic²⁴, Yannick Allanore²⁵, Francesco Del Galdo²⁶ and Michael Hughes²⁷, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁵Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rambam Heath Care Campus, Haifa, Israel, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Self employed, Montréal, Canada, ¹¹University of Florence, Florence, Florence, Italy, ¹²Ospedale San Raffaele, Milano, Italy, ¹³University College London, UK, London, United Kingdom, ¹⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁷University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁰Humanitas University, Pieve Emanuele, Italy, ²¹Waikato Hospital, Hamilton, New Zealand, ²²Medical University of Plovdiv, Plovdiv, Bulgaria, ²³"Erebuni" Medical Center, Yerevan, Armenia, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Université Paris Cité, Paris, France, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease characterized by vasculopathy, fibrosis, and immune dysregulation. While JAK inhibitors (JAKi) have shown promising immunomodulatory…
Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Carolina Ramirez-Becerra¹, Tulsi Joishy², Sheau-Chiann Chen², Marisol Ramirez-Solano², Quanhu Sheng², Peter Turnbaugh³, Carles Ubeda⁴, Renuka Nayak⁵, Rebecca Blank⁶, Jose Scher⁷ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of California, San Francisco, San Francisco, CA, ⁴Fisabio, Madrid, ⁵University of California, San Francisco (UCSF), San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…
Abstract Number: 1061 • ACR Convergence 2025
Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Daniel Austin¹, Beenish Zulfiqar², Akhil Adla¹, Jeffrey Zuber² and Joshua Sullivan³, ¹University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee Health Science Center & Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN, ³Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN
Background/Purpose: Hepatitis B virus (HBV) screening is insufficiently completed prior to initiation of immunosuppressive therapy nationwide. Various factors including alert fatigue, provider mistakes, non-compliance, and…
Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Sanjeev Kapoor¹, Babita Bondage¹, Niti Kedia¹, Mariya Patel¹ and Akanksha Kapoor², ¹Indian Spinal Injuries Centre (ISIC), New Delhi, India, ²Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Pune, India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…
Abstract Number: 0483 • ACR Convergence 2025
Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Clara De Miguel¹, Héctor Vega², Marta Sánchez², Esther Toledano³, Pedro Pablo Bermejo⁴, Leonor Laredo⁵, José Alberto Peña⁶, María Teresa Benítez⁷, DALIFER FREITES⁸, LETICIA LEON⁹ and lydia Abasolo Alcazar¹⁰, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Complutense University of Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ⁴Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁶Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁷San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ¹⁰IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) are chronic inflammatory arthritis (CIAs). Janus kinase inhibitors (JAKis) have emerged as a promising therapeutic…
Abstract Number: 0070 • ACR Convergence 2025
Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis
Chary López pedrera¹, Sagrario Corrales², Julio Osuna³, Rafaela Ortega-Castro⁴, Jerusalén Calvo⁵, Lourdes Ladehesa⁶, Ismael Sanchez-Pareja², Laura muñoz-Barrera², Desiree Ruiz-Vilchez⁷, Christian Merlo⁸, MARIA ANGELES AGUIRRE ZAMORANO², Nuria Barbarroja⁹, Tomás Cerdó², Marta Alarcon-Riquelme¹⁰, Carlos Pérez Sánchez¹¹, Alejandro Escudero Contreras⁵ and Concepción Aranda-Valera⁵, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁸Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁰Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
Abstract Number: 0317 • ACR Convergence 2024
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Pablo Moreno-Fresneda¹, Cristina Vadillo-Font², Fredeswinda Romero-Bueno³, Olga Sánchez-Pernaute⁴, Rosalía Laporta⁵, hildegarda Godoy Tundidor⁶, Belén López-Muñiz⁷, Laura Cebrián⁷, Claudia Valenzuela⁸, Irene Llorente-Cubas⁹, Jesús Loarce¹⁰, Juan Rigual¹⁰, Benjamin fernandez-Gutierrez¹¹, M Asuncion Nieto¹ and lydia Abasolo Alcazar¹², ¹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ²Hospital Clinico S Carlos, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁶Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ⁸ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ⁹Hospital Universitario de La Princesa, Madrid, Spain, ¹⁰Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ¹¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Spain
Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…

« Previous Page
1
…
6
7
8
9
10
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].